Expert Consultations: Real-World Answers

Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder – Interview

Published on August 1, 2023 Certification expiration date: August 1, 2026

Guest

Radwa Hanafy

To unlock this audio you need to become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

SSRIs remain to be first-line pharmacological options for the management of OCD. It is best to maximize SSRI dose before proceeding to augment these with other agents.
Deep TMS is now an FDA-approved option as an adjunctive strategy for the treatment of OCD. For patients with treatment-resistant OCD, neurosurgical interventions can be an effective option.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features David Osser, M.D., an associate professor of psychiatry at Harvard Medical School. In this interview, we will discuss the algorithm for the psychopharmacologic management of obsessive-compulsive disorder.

Radwa Hanafy, M.D.: Welcome to the Psychopharmacology Institute. You are listening to Expert Consultations and I'm your host, Dr. Radwa Hanafy. Today, we are back with another psychopharmacology algorithm

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

Summarize the appropriate treatment options for obsessive-compulsive disorder.
Discuss the evidence and efficacy of different augmentation options for patients with partial response to SSRIs.
Identify neuromodulatory and neurosurgical options for treatment-resistant obsessive-compulsive disorder.

Original Release Date: August 1, 2023

Review and Re-release Date: March 1, 2024

Expiration Date: August 1, 2026

Expert: David Osser, M.D.

Medical Editors: Radwa Hanafy, M.D., Melissa Mariano, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@ml-staging.psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

David Osser, M.D.